HUMAN NUTRACEUTICAL SUPPLEMENT

This invention relates to a human nutraceutical supplement and, specifically, a specific supplement for humans of the type specified in the preamble of the first claim.

As is well known, food is increasingly poor in fundamental elements for the human organism due to cultivation/breeding methods.

In particular, in recent years there has been a rapid increase in age-related and andropause health disorders leading to unpleasant androgenic disorders.

In particular, this nutritional deficiency can lead to the onset of many diseases such as inflammatory bladder syndromes, urinary disorders, benign prostatic hyperplasia, erectile dysfunction, depressive states, anxiety, neurological stress and lowered immune defences, and, increasingly frequently, tumours.

In this context, the technical task underlying this invention is to devise a human nutraceutical supplement that can largely overcome at least some of the above- mentioned drawbacks.

In the context of said technical task, it is an important purpose of the invention to obtain a human nutraceutical supplement able to counteract the nutritional deficiency and, therefore, the onset of many diseases, especially those affecting the male urogenital organs.

The technical task and the specified purposes are achieved by means of a human nutraceutical supplement as claimed in the appended claim 1 . Examples of preferred embodiments are described in the dependent claims.

In this document, the measures, values, shapes and geometric references (such as perpendicularity and parallelism), when associated with words like“almost” or other similar terms such as“approximately” or“substantially”, are to be understood as except for measurement errors or inaccuracies owing to production and/or manufacturing errors and, above all, except for a slight divergence from the value, measure, shape, or geometric reference with which it is associated. For example, if associated with a value, such terms preferably indicate a divergence of no more than 10% from the value itself.

The measurements and data provided in this text are to be considered as performed in ICAO International Standard Atmosphere (ISO 2533), unless otherwise indicated. The human nutraceutical supplement according to the invention is a nutraceutical supplement for people and, in particular, specifically for the male sex.

The human nutraceutical supplement is, preferably, in pill or sachet form.

The nutraceutical supplement may comprise the alkaloid muirapuamine. Specifically, it comprises extracts of Ptychopetalum olacoides or Muira puama, preferably from roots, branches and/or bark, comprising alkaloid muirapuamine. The content of Muira puama extracts essentially ranges between 20% and 1 %, specifically between 15% and 2%, and preferably between 10% and 5%. It can essentially be 8%.

In this document, the content of the various components is expressed as a % of the ratio between the weight of the component and the weight of the nutraceutical supplement.

The nutraceutical supplement may comprise catuabines, conveniently A, B, C, and D, and/or cinchonines. Specifically, it comprises Erythroxylum catuaba extracts, preferably from bark, comprising catuabines and/or cinchonines.

The content of Erythroxylum catuaba extracts is essentially lower than that of the Muira puama extracts. It is essentially less than 5% and, specifically, it essentially ranges between 5% and 1 %, and preferably between 3% and 2%. This content can essentially be 2.5%.

The nutraceutical supplement comprises damianin. Specifically, it comprises Turnera aphrodisiaca Willd. ex Schult extracts, preferably from leaves and/or roots, comprising damianin.

The content of Turnera aphrodisiaca Willd. ex Schult extracts is essentially equal to that of the Muira puama extracts. It essentially ranges between 20% and 1 %, specifically between 15% and 2%, and preferably between 10% and 5%. The content of Turnera aphrodisiaca Willd. ex Schult extracts can essentially be 8%. The nutraceutical supplement may comprise yohimbine. Specifically, it comprises Pausinystalia yohimbe (K. Schum.) extracts, preferably from bark, comprising yohimbine.

The content of Pausinystalia yohimbe extracts is essentially lower than that of Muira puama extracts. It is essentially lower than 5% and, specifically, it essentially ranges between 5% and 1 %, and preferably between 4% and 3%. This content can essentially be 3%.

The nutraceutical supplement comprises icariin. Specifically, it comprises Epimedium grandiflorum (also called Epimedium macranthum var. violaceum (C. Morren & Decne.)) extracts, preferably from dried leaf, comprising icariin.

The content of Epimedium grandiflorum extracts is essentially equal to that of Muira puama extracts. It essentially ranges between 20% and 1 %, specifically between 15% and 2%, and preferably between 10% and 5%. This content can essentially be 8%.

The nutraceutical supplement comprises Eurycomanone. Specifically, it comprises Eurycoma longifolia Jack extracts, preferably from the root, comprising Eurycomanone.

The content of Eurycoma longifolia Jack extracts is essentially equal to that of Muira puama extracts. It essentially ranges between 20% and 1 %, specifically between 15% and 2%, and preferably between 10% and 5%. This content can essentially be 8%.

The nutraceutical supplement comprises one or more of the following: genistein, daidzein, and arginine. Specifically, it comprises Glycine max L. extracts (hereinafter simply Glycine max), preferably from seeds, comprising genistein, daidzein, and arginine.

The content of Glycine max extracts is essentially equal to that of Muira puama extracts. It essentially ranges between 20% and 1 %, specifically between 15% and 2%, and preferably between 10% and 5%. This content can essentially be 8%.

The nutraceutical supplement may comprise beta-sitosterol. Specifically, it comprises Serenoa repens extracts, preferably from dried fruit, comprising beta- sitosterol.

The content of Serenoa repens extracts is essentially lower than that of Muira puama extracts. It is essentially less than 5% and, specifically, it essentially ranges between 5% and 1 %, and preferably between 4% and 3%. This content can essentially be 3%.

The nutraceutical supplement may comprise one or more of the following: cucurbitins, delta sterols, phytosterols, plant globulins, vitamin F and E. Specifically, it comprises Cucurbita pepo L. extracts (hereinafter simply Cucurbita pepo), preferably from seeds, comprising cucurbitins, delta sterols, phytosterols, plant globulins, vitamin F and E.

The content of Cucurbita pepo extracts is essentially lower than that of Muira puama extracts. It is essentially less than 5%, specifically than 3%, and, preferably, it essentially ranges between 2% and 1 %. This content can essentially be 1 .5%.

The nutraceutical supplement may comprise one or more of the following: isoflavones, policosanols, saponins, folic acid (conveniently in the 5- methyltetrahydrofolate form), and minerals (preferably magnesium, copper, and calcium). Specifically, it comprises Medicago sativa extracts (hereinafter simply Medicago sativa), preferably from leaves, comprising folic acid and (conveniently in the form of 5-methyltetrahydrofolate) and preferably isoflavones, policosanols, saponins, and minerals (preferably magnesium, copper, and calcium).

The content of Medicago sativa extracts is essentially lower than that of Muira puama extracts. It is essentially less than 5%, specifically than 3%, and preferably than 1 %. This content can essentially be 0.8%.

The nutraceutical supplement comprises at least one of the following: coenzyme Q10, Vitamin E, magnesium, calcium, or phosphorus. Specifically, it comprises Triticum turgidum extracts, preferably from wheat germ, comprising coenzyme Q10, Vitamin E, magnesium, calcium, and phosphorous.

The content of Triticum turgidum extracts is essentially lower than that of Muira puama extracts. It is essentially less than 5% and, specifically, it essentially ranges between 5% and 1 %, and preferably between 4% and 3%. This content can essentially be 3%.

The nutraceutical supplement may comprise one or more of the following: iron, calcium, silicon, magnesium, phosphorous, vitamin A, C, and K, formic and gallic acid, chlorophyll, tannins, carotene, and histamine. Specifically, it comprises Urtica dioica L. extracts (hereinafter simply Urtica dioica), preferably from leaves, comprising iron, calcium, silicon, magnesium, phosphorous, vitamin A, C, and K, formic and gallic acid, chlorophyll, tannins, carotene, and histamine.

The content of Urtica dioica extracts is essentially lower than that of Muira puama extracts. It is essentially lower than 5%, specifically than 3%, and, preferably, it essentially ranges between 2% and 1 %. This content can essentially be 1 .5%.

The nutraceutical supplement may comprise at least one of either resveratrol or pterostilbene. Specifically, it comprises Polygonum cuspidatum extracts, preferably from roots, comprising resveratrol and pterostilbene (conveniently in trans form). The content of Polygonum cuspidatum extracts is essentially equal to that of Muira puama extracts. It essentially ranges between 20% and 1 %, specifically between 15% and 2%, and preferably between 10% and 5%. This content can essentially be 8%.

The nutraceutical supplement comprises one or more of the following: pterostilbene, kino gum, tannins, and butein. Specifically, it comprises Butea frondosa extracts, preferably from roots, comprising pterostilbene, kino gum, tannins, and butein.

The content of Butea frondosa extracts is essentially equal to that of Muira puama extracts. It essentially ranges between 20% and 1 %, specifically between 15% and 2%, and preferably between 10% and 5%. This content can essentially be 8%.

The nutraceutical supplement comprises at least one of the following: pterostilbene, organic acids, pectins, tannins, myrtillin, anthocyanins, or vitamin A, C, and B. Specifically, it comprises Vaccinium myrtillus extracts, preferably from fruit, comprising: pterostilbene and preferably organic acids, pectins, tannins, myrtillin, anthocyanins, and vitamin A, C, and B.

The content of Vaccinium myrtillus extracts is essentially lower than or equal to that of Muira puama extracts. It essentially ranges between 20% and 1 %, specifically between 15% and 2%, and preferably between 10% and 5%. This content can essentially be 8%.

The nutraceutical supplement comprises at least one of either: resveratrol or pterostilbene (conveniently in trans form). Specifically, it comprises Vitis vinifera L. (hereinafter simply Vitis vinifera) extracts, preferably from grape skins and/or branches, comprising pterostilbene and preferably resveratrol.

The content of Vitis vinifera extracts is essentially equal to that of Muira puama extracts. It essentially ranges between 20% and 1 %, specifically between 15% and 2%, and preferably between 10% and 5%. This content can essentially be 8%.

In a preferred, non-binding formulation, the nutraceutical supplement may comprise Muira puama extracts (the content essentially ranging between 15% and 2% and, preferably, essentially 8%); Erythroxylum catuaba extracts (the content essentially ranging between 5% and 1 % and, preferably, essentially 2.5%); Turnera aphrodisiaca Willd. ex Schult extracts (the content essentially ranging between 15% and 2% and, preferably, essentially 8%); Pausinystalia yohimbe extracts (the content essentially ranging between 5% and 1 % and, preferably, essentially 3%); Epimedium grandiflorum extracts (the content essentially ranging between 15% and 2% and, preferably, essentially 8%); Eurycoma longifolia Jack extracts (the content essentially ranging between 15% and 2% and, preferably, essentially 8%); Glycine max extracts (the content essentially ranging between 15% and 2% and, preferably, essentially 8%); Serenoa repens extracts (the content essentially ranging between 5% and 1 % and, preferably, essentially 3%); Cucurbita pepo extracts (the content essentially lower than 3% and, preferably, 1 .5%); Medicago sativa extracts (the content essentially lower than 3% and, preferably, essentially 0.8%); Triticum turgidum extracts (the content essentially ranging between 5% and 1 % and, preferably, essentially 3%); Urtica dioica extracts (the content essentially lower than 3% and, preferably, essentially 1 .5%); Polygonum cuspidatum extracts (the content essentially ranging between 15% and 2% and, preferably, essentially 8%); Butea frondosa extracts (the content essentially ranging between 15% and 2% and, preferably, essentially 8%); Vaccinium myrtillus extracts (the content essentially ranging between 15% and 2% and, preferably, essentially 8%); and Vitis vinifera extracts (the content essentially ranging between 15% and 2% and, preferably, essentially 8%).

The extracts described above (phyto-complexes and/or fungi) can be obtained through a drying and titration process of the powders or by solvent extraction.

In some cases, they can be obtained by Soxhlet reflux extraction and, in particular, with ultrasound or supercritical gas, and the addition of sulphur dioxide as the solvent. These extracts are preferably obtained through the Soxhlet reflux method with methanol. This method comprises the fermentation and hydrolysis of the part of the plant (for example the fruit, flower, or leaf) from which the extracts are to be obtained, with the addition of yeast, appropriately Saccharomycetaceae (such as Saccharomyces cerevisiae) and preferably operating at pH 7 for about 4 days; evaporation and centrifugation to remove the solvent from the solution obtained above; Soxhlet extraction; methanol removal by boiling-point heating, and extraction thereof by evaporation.

The nutraceutical supplement according to the invention entails important advantages.

In fact, the innovative nutraceutical supplement, conveniently composed only of plant extracts (therefore natural and organic), has beneficial effects for a person. In particular, it is particularly effective in combatting disorders that predominantly afflict men and, to be precise, the male urogenital apparatus. These effects are primarily facilitated by the aphrodisiac, hormonal, and psychostimulant effects of the nutraceutical supplement. In fact, as demonstrated by the studies carried out by the inventor, the presence of the Turnera aphrodisiaca Willd. ex Schult extracts, thanks to their damianin content, have a parasympathetic action relaxing the central nervous system (favouring an increase in desire and counteracting erectile dysfunction problems) and, in addition, lead to an increase in sperm volume.

The relaxing action of the vasodilatory and psychoactive nervous system of damianin is assisted by Muira puama thanks to its muirapuamine content. This active ingredient strongly counteracts depression and also has aphrodisiac and tonic effects.

The nervous system- and psychoactive system-relaxing action of the above- mentioned two extracts is synergistically enhanced by the presence of: Triticum turgidum extracts, which improve mental efficiency thanks to the octacosanol content; Erythroxylum catuaba extracts, which have an aphrodisiac action; Erythroxylum that, thanks to its content of Catuabines A, B, C, and D, as well as Cinchonines (la and lb), stimulates the nervous system carrying out an antidepressant action; Eurycoma longifolia Jack that, by containing Eurycomanone, increases, with the assistance of Glycine max extracts that can stimulate SHBG, testosterone causing a marked increase in libido.

The ameliorative action on a man’s sexual capacity and function is increased by the nutraceutical supplement thanks to the Turnera aphrodisiaca Willd. ex Schult extracts that have an antioxidant action and counteract cellular mutations; Epimedium grandiflorum icariina extracts that, thanks to icariin, have an antioxidant and vasoprotective action; Glycine max extracts that, thanks to genistein and daidzein, in addition to antioxidant actions, have a protective action in relation to the cardiovascular system thanks to the platelet antiaggregant action and the ability to reduce LDL cholesterol and increase HDL; and by the resveratrol and pterostilbene present in the extracts of Polygonum Cuspidatum, Vitis vinifera, and Butea frondosa that have a strong antioxidant action and protective action in relation to the cardiovascular system.

Summing up, the nutraceutical supplement carries out, in terms of stimulating the male genital apparatus function, an important action thanks to the synergistic action of rebalancing the nervous system with a consequent increase in libido/stimulation (thanks to the extracts of Turnera aphrodisiaca Willd. ex Schult, Muira puama, Triticum turgidum, Erythroxylum catuaba, Eurycoma longifolia Jack, Glycine max) and an improvement of the cardiovascular system thanks to the active ingredients in the extracts of Turnera aphrodisiaca Willd. ex Schult, Epimedium grandiflorum icariina, Glycine max, Polygonum cuspidatum, Vitis vinifera, and Butea.

In addition, the active capacity of these components is further enhanced by the Triticum turgidum extracts exerting muscle stimulation and implementing nerve impulse conduction in the central nervous system by enhancing the above- mentioned effects.

The above-mentioned effects may be enhanced by the other components that can assist said extracts’ action.

In fact, the Pausinystalia yohimbe extracts are characterised by a high content of yohimbine, an active ingredient capable of both regulating the flow of neurotransmitters and promoting the dilation of blood vessels in the male genital organs.

The Serenoa repens extracts, containing beta-sitosterol, favour said improvement of the male genital apparatus thanks to their anti-inflammatory and antispasmodic action on the muscles of the urinary tract.

The Cucurbita pepo extracts assist the above-mentioned improvement of the functionality of the male genital apparatus, in particular, thanks to the content of cucurbitins, delta sterols, phytosterols, plant globulins, and vitamin F, and vitamin E assists the above-mentioned improvement of the cardiovascular system thanks to its antioxidant properties.

The action of the nutraceutical supplement on the cardiovascular system is enhanced by the Medicago sativa extracts thanks to their power, including that of reducing cholesterol levels and plaque deposits on the walls of the arteries.

Finally, the Urtica dioica extracts, carrying out an antianemic action, also contribute to improving the cardiovascular system.

A no-less important effect is the result of the absence of side effects in the extracts used and, therefore, in the nutraceutical supplement.

Variations may be made to the invention that fall within the scope of the inventive concept defined in the claims. All details may be replaced with equivalent elements and the scope of the invention includes all other materials, shapes, and dimensions.